Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals is a biotech powerhouse that specialises in developing life-changing medicines for serious, often rare, genetic conditions.
Is Vertex Pharmaceuticals Incorporated a good stock for a UK beginner?
The honest version: Vertex Pharmaceuticals is a biotech powerhouse that specialises in developing life-changing medicines for serious, often rare, genetic conditions.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Vertex becomes a multi-disease leader with several blockbuster drugs.
Failure to innovate beyond their current core products.
What does Vertex Pharmaceuticals Incorporated do?
Vertex is best known for its dominant position in treating cystic fibrosis, a condition where it has effectively created a monopoly through its specialised drugs. Selling these high-value treatments to patients worldwide funds the business, with those profits reinvested into researching new therapies for other complex diseases. Keep an eye on how successfully they expand beyond their core cystic fibrosis business into new areas like gene editing and pain management.
On our factor screen it looks strongest on quality and growth, and weakest on income.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 8% over the year
- ✓Very profitable - turns about 36% of sales into profit
- ✓Low debt - a sturdier balance sheet
- ✓Strong return on shareholder money (ROE 24%)
- Quality screens high (79/100)
- Dominant market position in cystic fibrosis
- Very high profit margins
- Strong track record of scientific innovation
- Income screens low (16/100)
- High failure rate of new drug development
- Potential for government pressure on drug pricing
- Patent expirations could open the door to cheaper rivals
What do Vertex Pharmaceuticals Incorporated's numbers mean?
How much money does Vertex Pharmaceuticals Incorporated make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Vertex Pharmaceuticals Incorporated pay a dividend?
No - Vertex Pharmaceuticals Incorporated doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does Vertex Pharmaceuticals Incorporated report earnings, and how did recent quarters go?
Vertex Pharmaceuticals Incorporated is next scheduled to report on about 2026-08-03 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-05-04 | $4.31 | $4.47 | Beat +4% |
| 2026-02-12 | $5.15 | $5.03 | Missed -2% |
| 2025-11-03 | $4.58 | $4.80 | Beat +5% |
| 2025-08-04 | $4.25 | $4.52 | Beat +6% |
| 2025-05-05 | $4.29 | $4.06 | Missed -5% |
| 2025-02-10 | $4.02 | $3.98 | Missed -1% |
Across the last 6 quarters here, Vertex Pharmaceuticals Incorporated came in ahead of what analysts expected 3 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Vertex Pharmaceuticals Incorporated?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Vertex Pharmaceuticals Incorporated?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Dominant market position in cystic fibrosis
- Very high profit margins
- Strong track record of scientific innovation
- Low share price volatility compared to the market
- Heavy reliance on a single area of medicine
- No dividend payments for income-focused investors
- High price-to-sales ratio suggests a premium valuation
- High failure rate of new drug development
- Potential for government pressure on drug pricing
- Patent expirations could open the door to cheaper rivals
The write-up's own warning lights — if these start happening, the case above changes.
- A major, unexpected failure in a key clinical trial
- A significant change in how governments reimburse expensive drugs
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.